Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02232984 · ClinicalTrials.gov registry record
Quadripolar CRT-D On Currently Approved Lead SystemS
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 749
- Enrollment target
NCT02232984: Completed study, sponsored by Boston Scientific Corporation.
NCT02232984 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 749 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02232984 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 749 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate different ways to program around extracardiac stimulation.
Primary Outcome
The primary objective of this study was to characterize the performance of Boston Scientific (BSC) unique pacing vectors vs. BSC/St Jude Medical (STJ) common pacing vectors to prevent phrenic nerve stimulation (PNS) based on the selected pacing cathode. BSC unique vectors are those that are only available with Boston Scientific's (BSC) quadripolar (X4) CRT-Ds while common vectors are those that are available for both BSC and STJ systems.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 749 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-10 |
What the finished NCT02232984 record still lists
NCT02232984 is an observational study that tracks outcomes without assigning an intervention. The registered 749 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02232984 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02232984 about?
NCT02232984 is a clinical study titled "Quadripolar CRT-D On Currently Approved Lead SystemS". The purpose of the study is to evaluate different ways to program around extracardiac stimulation.
What is the current status of trial NCT02232984?
This trial is currently completed. The enrollment target is 749 participants. The study started on 2014-10. Estimated completion is 2016-10.
Who is sponsoring clinical trial NCT02232984?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia